Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01709019 · ClinicalTrials.gov registry record · Phase 1
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
A Phase 1 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
NCT01709019 is a Phase 1 study that has completed, run by Novavax. The registered enrollment target is 220 participants.
The verdict
NCT01709019, a Phase 1 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
Study Summary
Up to 220 eligible subjects will be enrolled into one of five treatment groups. It is anticipated that some of the randomized study subjects may not complete the study; subjects who withdraw or are discontinued, will not be replaced. Randomization will be stratified by age (60 to \<75 years and ≥ 75 years) in order to distribute the proportion of such persons in each age group equally across treatment groups. Treatments will comprise a single IM dose of a placebo or RSV-F protein nanoparticle vaccine on Day 0, with concurrent IM immunization with a licensed inactivated influenza vaccine. A rescue dose of the licensed TIV will be provided to subjects in all groups except the placebo group on Day 28, the placebo group will receive saline. For each subject, study follow-up will span approximately one year from the first immunization (on Day 0) for all subjects.
Interventions
- BIOLOGICAL Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
- BIOLOGICAL Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)
- BIOLOGICAL High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
- BIOLOGICAL High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
- BIOLOGICAL Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01709019
The ClinicalTrials.gov registry entry for NCT01709019 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28) is the first listed.
NCT01709019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01709019 about?
NCT01709019 is a clinical study titled "RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly". Up to 220 eligible subjects will be enrolled into one of five treatment groups. It is anticipated that some of the randomized study subjects may not complete the study; subjects who withdraw or are discontinued, will not be replaced. Randomization will be stratified by age (60 to \<75 years and ≥ 75...
What is the current status of trial NCT01709019?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2012-10. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01709019?
The interventions under investigation include: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28) (BIOLOGICAL), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28) (BIOLOGICAL), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28) (BIOLOGICAL), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28) (BIOLOGICAL), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01709019?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.